sofosbuvir + raltegravir + emtricitabine + tenofovir disoproxil fumarate

This is a combination regimen consisting of **sofosbuvir**, **raltegravir**, **emtricitabine**, and **tenofovir disoproxil fumarate**, used as part of antiretroviral therapy for co-infection or complex management cases involving both HIV and HCV. - **Sofosbuvir**: A nucleotide analog inhibitor of the HCV NS5B polymerase, used for hepatitis C treatment. - **Raltegravir**: An HIV-1 integrase strand transfer inhibitor (INSTI), blocking the integration of viral DNA into the host genome. - **Emtricitabine** and **tenofovir disoproxil fumarate**: Both are nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), inhibiting HIV reverse transcriptase and thus blocking viral replication. This specific four-drug regimen is not an approved, branded fixed combination but may be used in clinical practice where both HIV and HCV infections are treated concurrently, dependent on patient-specific considerations[2][5].